The FDA Commissioner Who Tried to Kill a Drug Approval

But here's what makes this unusual. Commissioners don't typically intervene in individual drug approval decisions. The FDA's structure is designed to keep those calls in the hands of career scientists who've spent months reviewing clinical data. The commissioner sets policy, priorities, and the overall direction of the agency. Deciding whether Drug X gets a green light? That's not in the job description.

Senior FDA staff apparently agreed. Sources told Endpoints that scientists warned the rejection could be considered "arbitrary and capricious" under administrative law, a legal standard that essentially means a government action has no reasonable basis. That warning was apparently enough; the push for rejection was dropped.

HHS publicly called the allegation "totally false and untrue." So we're left with a he-said, she-said between unnamed agency insiders and official government denials.

The PDUFA Miss That Set the Stage

Before the alleged rejection attempt, there was already a sign that something was off. KalVista disclosed that the FDA would miss its June 17, 2025 PDUFA date for sebetralstat. PDUFA dates are the FDA's self-imposed deadlines for making approval decisions; they're funded by fees that drug companies pay specifically to keep reviews on schedule.

The reason given? "Heavy workload and limited resources." Not a data problem. Not a safety signal. Just not enough hands on deck.

For a rare disease company counting on a predictable timeline, that's like being told your flight is delayed because the airline forgot to schedule a pilot. The system is supposed to prevent exactly this.

KalVista's CEO said at the time that FDA staff had been "nothing but professional," framing the delay as a temporary hiccup. The drug was approved roughly two weeks after the missed deadline. But the episode, combined with the later reporting about the commissioner's involvement, painted a more complicated picture.

Why This Matters Beyond One Drug

Let's zoom out. KalVista got its approval. Patients with HAE now have access to EKTERLY. The company is even preparing a new application for children ages 2 to 11, expected to be submitted in Q3 2026. By the numbers, this story has a happy ending.

But the precedent (or near-precedent) is what should worry the biotech industry.

The FDA approved 23 orphan-designated drugs among its 46 novel approvals through CDER in 2025. The agency has an entire framework, called Accelerating Rare Disease Cures (ARC), dedicated to getting treatments to patients with conditions that affect small populations. A policy shift in late 2025 even allowed applications to move forward based on one strong study plus confirmatory evidence, lowering the bar meaningfully for rare disease developers.

All of that progress depends on one thing: predictability. Biotech companies spend hundreds of millions of dollars and a decade or more developing drugs for tiny patient populations. The math only works if they can trust that a solid dataset leads to a fair review, and that political actors won't insert themselves at the last minute.

If commissioners start weighing in on individual approvals, the calculus changes. Stifel analyst Paul Matteis called the commissioner's reported involvement "surprising and unusual" while maintaining a Buy rating on KalVista. That's Wall Street code for: "This is weird, but we don't think it'll happen again."

Let's hope he's right.

The Bigger FDA Picture

KalVista's saga doesn't exist in a vacuum. The FDA has been juggling several high-profile situations simultaneously, including an ongoing investigation into patient deaths linked to Sarepta Therapeutics' Duchenne gene therapy, Elevidys. The agency investigated at least two deaths in non-ambulatory patients associated with acute liver failure, suspended distribution at one point, and placed certain Sarepta gene therapy trials on hold.

These are the kinds of decisions the FDA was built to make: weighing risks, protecting patients, and using scientific evidence to draw difficult lines. That process works best when it's insulated from political winds, regardless of which direction those winds are blowing.

Historians and policy experts have warned about this for years. One Harvard analysis noted concern about "more politicization of the agency than is either warranted by rational politics or good for the American people." The KalVista episode, even if the official denials are taken at face value, shows how thin the line between policy influence and scientific interference has become.

What Comes Next

KalVista's stock weathered the storm. Analysts still lean Outperform. The company's pediatric expansion is on track. EKTERLY is approved in multiple countries.

But the biotech industry has a long memory. Every rare disease developer watching this story is asking the same question: if it can happen to KalVista, can it happen to me?

The answer, for now, is that the system held. The scientists pushed back, the drug got approved, and the patients won. But "the system held" is a lot less comforting than "it was never in danger." And that distinction might be the most important takeaway from this whole episode.

J&J Just Locked Down a $5 Billion Drug Until 2035. Generics Can't Touch It.

A federal court just blocked generic Spravato until 2035, handing J&J a decade of exclusivity on a drug headed toward $5 billion in peak sales. For generics companies, the ruling is a costly warning shot.